Best Cannabis Biotech Stocks
Updated March 2026Cannabis biotech and pharmaceutical companies developing cannabinoid-based medicines, ranked by market capitalization.
Cannabis biotech stocks represent the pharmaceutical and scientific frontier of the marijuana industry. These companies are developing cannabinoid-based therapies for conditions ranging from epilepsy and chronic pain to anxiety, PTSD, and rare diseases. Unlike traditional cannabis companies that sell consumer products, biotechs are pursuing FDA-approved pharmaceuticals through clinical trials — a longer, more expensive, but potentially far more valuable path.
The cannabis biotech space has already produced one blockbuster success: Epidiolex (cannabidiol), which was approved by the FDA for rare forms of epilepsy and generated over $700 million in annual revenue before being acquired by Jazz Pharmaceuticals. This proof of concept demonstrated that cannabinoid-based medicines can win regulatory approval and achieve commercial success, validating the thesis for other companies in the pipeline.
Biotech stocks behave very differently from other cannabis equities. Their valuations are driven by clinical trial data, FDA regulatory milestones, and patent portfolios rather than quarterly revenue and margin metrics. A single positive Phase 2 trial result can double a biotech stock overnight, while a clinical failure can wipe out 50-80% of market value. The ranking below sorts cannabis biotechs by market capitalization, reflecting the market's current assessment of each company's pipeline value.
Best Cannabis Biotech Stocks — Full Rankings
6 stocks · Ranked by market cap
| # | Ticker | Name | Price | Change | Market Cap | Revenue | Margin | P/S | Market Cap |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JAZZ | Jazz Pharmaceuticals | $178.55 | -1.66% | $10.99B | $4.16B | — | 2.64x | $10.99B |
| 2 | INNPF | InnocanPharma | $5.07 | 0.00% | $354.9M | $0 | — | — | $354.9M |
| 3 | CNVCF | BioHarvest Sciences | $5.71 | +1.33% | $57.1M | $0 | — | — | $57.1M |
| 4 | ZYNE | Zynerba Pharmaceuticals | $1.30 | +3.17% | $33.8M | $0 | — | — | $33.8M |
| 5 | XXII | 22nd Century Group | $3.88 | +1.97% | $2.0M | $18.1M | 36.3% | 0.11x | $2.0M |
| 6 | OVATF | Ovation Science | $0.02 | 0.00% | $623.3K | $0 | — | — | $623.3K |
Top 3 Spotlight
Jazz Pharmaceuticals
Jazz Pharmaceuticals ranks #1 in the best cannabis biotech stocks category with a share price of $178.55 and a market capitalization of $10.99B. The company operates in the Biotech sector and is listed on the NASDAQ. With trailing twelve-month revenue of $4.16B and a gross margin of N/A, JAZZ represents the top-ranked stock in this category based on market cap.
InnocanPharma
InnocanPharma ranks #2 in the best cannabis biotech stocks category with a share price of $5.07 and a market capitalization of $354.9M. The company operates in the Biotech sector and is listed on the OTC. With trailing twelve-month revenue of $0 and a gross margin of N/A, INNPF represents the second-ranked stock in this category based on market cap.
BioHarvest Sciences
BioHarvest Sciences ranks #3 in the best cannabis biotech stocks category with a share price of $5.71 and a market capitalization of $57.1M. The company operates in the Biotech sector and is listed on the OTC. With trailing twelve-month revenue of $0 and a gross margin of N/A, CNVCF represents the third-ranked stock in this category based on market cap.
Methodology
Stocks are filtered to include only companies classified as Biotech (cannabinoid pharmaceuticals and research) and ranked in descending order by market capitalization. Data is sourced from company filings, exchange feeds, and financial data providers. Rankings update automatically as new data becomes available. All financial figures are based on trailing twelve-month (TTM) data unless otherwise noted. The current ranking includes 6 qualifying stocks out of 100 total cannabis companies tracked by Cannabismarketcap.
Key Observations
The top-ranked stock in the best cannabis biotech stocks category is JAZZ (Jazz Pharmaceuticals) with a market cap of $10.99B. The stock trades at $178.55 per share with a market capitalization of $10.99B. In second place is INNPF ($354.9M), followed by CNVCF ($57.1M) in third.
Across all 6 qualifying stocks, the average share price is $32.42 and the average market capitalization is $1.91B. The combined trailing twelve-month revenue of all companies in this category is $4.18B. The average gross margin among companies with positive margins is 36.3%. The average price-to-sales ratio is 1.38x.
The most represented sector in this category is Biotech with 6 out of 6 companies (100%). Among the ranked stocks, 3 are trading higher today while 1 are trading lower. Investors should use these observations as a starting point for further research rather than as the basis for trading decisions.
Investment Considerations
When evaluating stocks in the best cannabis biotech stocks category, consider looking beyond the primary ranking metric to build a holistic view of each company. A stock that ranks well by market cap may have weaknesses in other areas — such as high debt, poor margins, or slowing growth — that the ranking alone does not capture. Cross-reference this list with other Cannabismarketcap category pages and the screener tool to identify stocks that score well across multiple dimensions.
Position sizing is particularly important in cannabis. The sector is inherently volatile, and even the strongest companies can experience 30-50% drawdowns during sector-wide sell-offs triggered by legislative disappointments or broader market risk-off events. Most financial advisors suggest limiting total cannabis exposure to 5-15% of your portfolio, and individual positions to 1-3% depending on your risk tolerance and conviction level.
Dollar-cost averaging (DCA) is a widely recommended approach for building cannabis stock positions over time. Rather than investing your entire allocation at a single price point, spreading purchases across weeks or months can reduce the impact of short-term volatility and lower your average cost basis if prices decline after your initial purchase. This strategy is particularly relevant for the stocks in this category given the sector's history of sharp and sometimes prolonged drawdowns.
Risk Factors
Risk Warning
Cannabis biotech stocks carry the full spectrum of traditional biotech risks: clinical trial failure (the majority of drug candidates fail to win FDA approval), lengthy and expensive development timelines (10+ years and hundreds of millions in capital), patent challenges, regulatory uncertainty specific to cannabinoid scheduling, and the need for significant capital raises to fund ongoing research. Unlike revenue-generating MSOs and LPs, many cannabis biotechs are pre-revenue or early-revenue companies whose stock prices are driven almost entirely by speculative assessments of pipeline value. Diversification across multiple biotechs is essential because any single company's primary drug candidate could fail.
Compare These Stocks
Head-to-head comparisons between top-ranked stocks in this category.
Frequently Asked Questions
How are cannabis biotech stocks different from regular cannabis stocks?
Cannabis biotechs develop FDA-regulated pharmaceutical products from cannabinoid compounds, while regular cannabis companies sell consumer cannabis products (flower, edibles, concentrates) under state regulatory frameworks. Biotechs typically go through rigorous and expensive clinical trials, pursue patents on their formulations and delivery methods, and aim for FDA approval that would allow their products to be prescribed by doctors and covered by insurance. This creates a fundamentally different risk/reward profile: higher potential valuations if successful, but much higher failure rates and longer timelines to commercialization.
What conditions are cannabis biotechs targeting?
Cannabis biotech companies are developing therapies for a wide range of conditions including rare forms of epilepsy (where Epidiolex set the precedent), chronic pain (as a potential alternative to opioids), anxiety disorders, PTSD, autism spectrum disorders, neurodegenerative diseases, chemotherapy-induced nausea, inflammatory conditions, and various rare diseases. Some companies focus on specific cannabinoids (CBD, THC, CBG, CBN), while others develop synthetic cannabinoid analogs designed to target specific receptors in the endocannabinoid system.
How should I evaluate a cannabis biotech stock?
Evaluating cannabis biotechs requires a different framework than other cannabis stocks. Key factors include the clinical trial stage of lead drug candidates (Phase 1, 2, or 3), the strength and breadth of the patent portfolio, the size of the addressable patient population for target indications, the quality and track record of the management and scientific advisory team, cash runway relative to upcoming trial milestones, and any partnerships with larger pharmaceutical companies that validate the technology. Revenue and margins are less relevant for pre-commercial biotechs.
Are cannabis biotech stocks affected by cannabis legalization efforts?
Indirectly, yes. Federal legalization or rescheduling could make it easier for cannabis biotechs to conduct research, source materials, and navigate FDA regulatory pathways. However, biotechs are less directly impacted than plant-touching companies because they already operate within the FDA regulatory framework and often work with synthetic or highly purified cannabinoid compounds rather than raw cannabis plant material. In some scenarios, broader legalization could actually reduce the perceived need for prescription cannabinoid medicines if consumers can access similar benefits through legal retail cannabis products.
More on Cannabismarketcap
Disclaimer: The information on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Cannabis stocks are highly speculative and carry significant risk of loss, including the potential loss of your entire investment. Past performance is not indicative of future results. The rankings and data presented are based on publicly available financial information and may contain errors or omissions. Always do your own research and consult with a qualified financial advisor before making investment decisions. Cannabismarketcap is not a registered investment advisor, broker-dealer, or financial planner.